Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
批准号:
8234168
负责人:
ELIZABETH MARY SWISHER
金额:
$31.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-08 至 2014-02-28
关键词:
AgeAllelesBRCA1 MutationBRCA1 geneCDKN1B geneCDKN1C geneCarcinomaCellsChemopreventionChildClinicalDevelopmentDiseaseEarly DiagnosisEpithelialEpitheliumFemaleFrequenciesGene Expression ProfileGenesGenital systemGoalsHereditary Ovarian CarcinomaHigh Risk WomanImmunohistochemistryInheritedLeadLesionLocationMalignant - descriptorMalignant NeoplasmsMammalian OviductsMicroinvasiveMolecular ProfilingMutationNeoplasmsOperative Surgical ProceduresOvarianOvarian CarcinomaPeritonealPhenotypePremalignantPreventionPreventiveProteinsProtocols documentationQuantitative Reverse Transcriptase PCRRecommendationRiskSalpingo-OophorectomyScreening procedureSerousSpecimenTimeWomanabstractingdesignfimbriahigh riskimprovedlifetime riskmalignant phenotypemutation carrierneoplastic cellnovel strategiesovarian neoplasmprotein expressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The lack of an identifiable precursor lesion for ovarian carcinoma hinders attempts to design rational
surveillance and chemoprevention for this deadly disease. Indeed, it is uncertain which are the specific cells in
the female genital tract that transform into ovarian and primary peritoneal malignancies. A better understanding
of the early steps in ovarian tumorigenesis would facillitate the development of new screening and prevention
stratgies. Inherited mutations in the BRCA1 gene results in an approximate 40% lifetime risk of ovarian, tubal
or peritoneal carcinoma. Current clinical recommendations for women with BRCA1 mutations include risk-
reducing salpingo-oophorectomy (RRSO) by age 40 after completion of child-bearing. Our group and others
have identified a high rate of high grade serous neoplasia in the fallopian tubes of BRCA1 mutation carriers
undergoing RRSO. The frequency of occult tubal neoplasia exceeds that of ovarian neoplasia when using a
detailed surgical and pathological protocol. We hypothesize that most ovarian and peritoneal carcinomas
arising in BRCA1 mutation carriers are seeded from neoplastic cells arising in the fallopian tubes. This
phenomenon could have important implications for the development of sporadic as well as hereditary ovarian
carcinoma. The overall goal of the current proposal is to define a premalignant tubal phenotype in women with
inherited BRCA1 mutations. The specific aims of this proposal are:
1. Characterize tubal epithelium in unaffected women with BRCA1 mutations and in women with BRCA1-
associated or sporadic ovarian and peritoneal carcinomas.
2. Identify and characterize a gene expression signature associated with premalignant alterations in
pathologically normal tubal epithelium from women with BRCA1 mutations.
3. Evaluate priority genes from Specific Aim 2 in inherited and sporadic ovarian and peritoneal carcinomas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
-
批准号:10661251
-
项目类别:
-
资助金额:$64.9万
-
财政年份:2023
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
-
批准号:10028143
-
项目类别:
-
资助金额:$45.95万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
-
批准号:10405502
-
项目类别:
-
资助金额:$45.5万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
-
批准号:10200719
-
项目类别:
-
资助金额:$44.57万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
-
批准号:9893364
-
项目类别:
-
资助金额:$64.52万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
-
批准号:10378133
-
项目类别:
-
资助金额:$59.67万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
-
批准号:10670755
-
项目类别:
-
资助金额:$58.53万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Implementing the moon: Getting genomic testing to the public
-
批准号:10228866
-
项目类别:
-
资助金额:$13.49万
-
财政年份:2019
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
-
批准号:7648344
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
-
批准号:7837669
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
-
批准号:8068733
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient
-
批准号:7727522
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
-
批准号:8445430
-
项目类别:
-
资助金额:$29.52万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:7122817
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:6787334
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:6937172
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:6666840
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:6507573
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient
-
批准号:8523019
-
项目类别:
-
资助金额:$26.28万
-
财政年份:--
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient
-
批准号:8077356
-
项目类别:
-
资助金额:$27.37万
-
财政年份:--
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
海外基金